BeiGene exploring commercialization options for returned PD-1 inhibitor

After regaining global rights to PD-1 inhibitor tislelizumab from Celgene, BeiGene is exploring options to commercialize the asset on its own or find a partner for the product in the U.S., Europe and Japan. The deal termination came as no surprise to BeiGene, and doesn't shift its global development strategy given the advanced stage of the deal and trials.

In May, BeiGene Chief Adviser Eric Hedrick told BioCentury that BeiGene “operationalized” about 90% of the PD-1 program. "The way we have the program structured, there isn't going to be a big impact on the nature of the program regardless of whether we or Celgene hold global rights," he said...